Skip to main content

Advertisement

SpringerLink
Log in

Novel Approaches for the Management of AL Amyloidosis

  • Multiple Myeloma (P Kapoor, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Light-chain-associated (AL) amyloidosis is a rare disease with a poor prognosis. However, we have made recent strides in more accurate diagnosis and effective treatment. Here, we discuss the most recent updates and advancements during the past year in the diagnosis, prognostication, and management of AL amyloidosis both in the upfront and relapsed setting.

Recent Findings

New imaging modalities, such as cardiac magnetic resonance (CMR) and use of fluorine-labeled radiotracers, are emerging as an important diagnostic tool in conjunction with biomarkers in the diagnosis, prognosis, and monitoring of the effects of therapy. In addition, ongoing evaluation of plasma cell-directed therapeutics, including daratumumab, pomalidomide, and ixazomib, as well as promising targeted novel therapies, such as the monoclonal antibody NEOD001, are in development.

Summary

In conclusion, incorporating the use of plasma cell-directed therapy and novel agents targeting the amyloid deposits itself hold enormous potential in achieving improved outcomes in AL amyloidosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nuvolone M, Merlini G. Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis. Expert Opin Ther Targets. 2017;21(12):1095–110.

    Article  PubMed  CAS  Google Scholar 

  2. Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O'Fallon WM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79(7):1817–22.

    PubMed  CAS  Google Scholar 

  3. Kaufman GP, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol. 2015;90(3):181–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751–7.

    Article  PubMed  CAS  Google Scholar 

  5. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–95.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Swiger KJ, Friedman EA, Brittain EL, Tomasek KA, Huang S, Su YR, et al. Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis. Amyloid. 2016;23(4):242–8.

    Article  PubMed  CAS  Google Scholar 

  7. Kristen AV, Rosenberg M, Lindenmaier D, Merkle C, Steen H, Andre F, et al. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis. Amyloid. 2014;21(3):202–10.

    Article  PubMed  CAS  Google Scholar 

  8. Dispenzieri A, Gertz MA, Saenger A, Kumar SK, Lacy MQ, Buadi FK, et al. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. Am J Hematol. 2015;90(6):524–8.

    Article  PubMed  CAS  Google Scholar 

  9. Andrikopoulou E, Bhambhvani P. Nuclear imaging of cardiac amyloidosis. J Nucl Cardiol. 2017;

  10. Falk RH, Quarta CC, Dorbala S. How to image cardiac amyloidosis. Circ Cardiovasc Imaging. 2014;7(3):552–62.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Liu D, Hu K, Niemann M, Herrmann S, Cikes M, Stork S, et al. Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013;6(6):1066–72.

    Article  PubMed  Google Scholar 

  12. Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076–84.

    Article  PubMed  Google Scholar 

  13. Bravo PE, Dorbala S. Targeted nuclear imaging probes for cardiac amyloidosis. Curr Cardiol Rep. 2017;19(7):59.

    Article  PubMed  Google Scholar 

  14. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–12.

    Article  PubMed  CAS  Google Scholar 

  15. Cappelli F, Gallini C, di Mario C, Costanzo EN, Vaggelli L, Tutino F, et al. Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis. J Nucl Cardiol. 2017;

  16. Stats MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol. 2016;25(5):413–7.

    Article  PubMed  CAS  Google Scholar 

  17. Boynton SJ, Geske JB, Dispenzieri A, Syed IS, Hanson TJ, Grogan M, et al. LGE provides incremental prognostic information over serum biomarkers in AL cardiac amyloidosis. JACC Cardiovasc Imaging. 2016;9(6):680–6.

    Article  PubMed  Google Scholar 

  18. Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2017;70(4):466–77.

    Article  PubMed  CAS  Google Scholar 

  19. Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52(8):1210–7.

    Article  PubMed  Google Scholar 

  20. Kaufman GP, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017;130(7):900–2.

    Article  PubMed  CAS  Google Scholar 

  21. Sanchorawala V, et al. Safety and tolerability of daratumumab in patients with relapsed light chain (AL) amyloidosis: preliminary results of a phase II study. Blood. 2017;130

  22. Roussel M, et al. A prospective phase II of daratumumab in previously-treated systemic light chain (AL) amyloidosis. Blood. 2017;130

  23. Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597–605.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  24. Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, et al. A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood. 2017;129(15):2120–3.

    Article  PubMed  CAS  Google Scholar 

  25. Sanchorawala V, Shelton AC, Lo S, Varga C, Sloan JM, Seldin DC. Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood. 2016;128(8):1059–62.

    Article  PubMed  CAS  Google Scholar 

  26. Leung N, Thome SD, Dispenzieri A. Venetoclax induced a complete response in a patient with AL amyloidosis plateaued on CyBorD. Haematologica. 2018;103:e135–7.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Gertz MA, Landau HJ, Weiss BM. Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody. Am J Hematol. 2016;91(12):E506–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, et al. First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol. 2016;34(10):1097–103.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Wechalekar AD, Whelan C. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. Blood Cancer J. 2017;7(3):e546.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Kumar S, et al. Doxycycline used as post transplant antibacterial prophylaxis improves survival in patients with light chain amyloidosis undergoing autologous stem cell transplantation. Blood. 2012;120

  31. D'Souza A, M.e.a. Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): a phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. Contemp Clin Trials, 2017; 8: 33–38.

  32. Chari, A.et al. Subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (RRMM): Pavo, an open-label, multicenter, dose escalation phase 1b study. 2017.

  33. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–34.

    Article  PubMed  CAS  Google Scholar 

  34. Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017;130(22):2401–9.

    Article  PubMed  CAS  Google Scholar 

  35. Kaufman J, et al. Phase 1 study of venetoclax in combination with dexamethasone as targeted therapy for t(11;14) relapsed/refractory mulitple myeloma, in ASH. Atlanta, GA.

  36. Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017;130(22):2392–400.

    Article  PubMed  CAS  Google Scholar 

  37. Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015;33(12):1371–8.

    Article  PubMed  CAS  Google Scholar 

  38. Rosenzweig M, Urak R, Walter M, Lim L, Sanchez JF, Krishnan A, et al. Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis. Cytotherapy. 2017;19(7):861–6.

    Article  PubMed  CAS  Google Scholar 

  39. Solomon A, Weiss DT, Wall JS. Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4. Clin Cancer Res. 2003;9(10 Pt 2):3831S–8S.

    PubMed  CAS  Google Scholar 

  40. Wall JS, Kennel SJ, Stuckey AC, Long MJ, Townsend DW, Smith GT, et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood. 2010;116(13):2241–4.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Edwards CV, et al. Final analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with relapsed or refractory AL amyloidosis. Blood. 2017;130

  42. Edwards CV, Gould J, Langer AL, Mapara M, Radhakrishnan J, Maurer MS, et al. Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Amyloid. 2017;24(sup1):58–9.

    Article  PubMed  Google Scholar 

  43. Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med. 2015;373(12):1106–14.

    Article  PubMed  CAS  Google Scholar 

  44. Meshitsuka S, Shingaki S, Hotta M, Goto M, Kobayashi M, Ukawa Y, et al. Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis. Int J Hematol. 2017;105(3):295–308.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Winship Cancer Institute, Emory University, 1365C Clifton Road, Atlanta, GA, 30322, USA

    Nisha S. Joseph & Jonathan L. Kaufman

Authors
  1. Nisha S. Joseph
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan L. Kaufman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan L. Kaufman.

Ethics declarations

Conflict of Interest

Jonathan L. Kaufman is a consultant for Amgen, Abbvie, Takeda, Sutro, Roche, and Seattle Genetics. The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Multiple Myeloma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Joseph, N.S., Kaufman, J.L. Novel Approaches for the Management of AL Amyloidosis. Curr Hematol Malig Rep 13, 212–219 (2018). https://doi.org/10.1007/s11899-018-0450-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-018-0450-1

Keywords

Search

Navigation